DAMGO TFA is a μ-opioid receptor (μ-OPR ) selective agonist with a Kd of 3.46 nM for native μ-OPR. An enkephalin analog that selectively binds to the MU OPIOID RECEPTOR. It is used as a model for drug permeability experiments.
CAT No: R1969
CAS No: 950492-85-0
Chemical Name: (2S)-2-amino-N-[(2R)-1-[[2-[[(2S)-1-(2-hydroxyethylamino)-1-oxo-3-phenylpropan-2-yl]-methylamino]-2-oxoethyl]amino]-1-oxopropan-2-yl]-3-(4-hydroxyphenyl)propanamide
Quick InquiryCustom Peptide SynthesisRegistration of APIs CMC information required for an IND
IND and NDA support Drug master files (DMF) filing
Synonyms/Alias | DAMGO;DAGO;78123-71-4;glyol;Dagol;DAMGE;2-Ala-4-mephe-5-gly-enkephalin;Tyr-ala-gly-(nme)phe-gly-ol;RX 783006;(D-Ala(2)-mephe(4)-gly-ol(5))enkephalin;(2S)-2-amino-N-[(2R)-1-[[2-[[(2S)-1-(2-hydroxyethylamino)-1-oxo-3-phenylpropan-2-yl]-methylamino]-2-oxoethyl]amino]-1-oxopropan-2-yl]-3-(4-hydroxyphenyl)propanamide;Enkephalin, ala(2)-mephe(4)-gly(5)-;CHEBI:272;CHEMBL38874;Tyr-D-Ala-Gly-MePhe-Gly-ol;Enkephalin, alanyl(2)-methylphenylalanyl(4)-glycine(5)-;950492-85-0;[3H]DAMGO;Tyr-D-Ala-Gly-MePhe-Gly(ol);Tyr-D-Ala-Gly-NMe-Phe-Gly-ol;Tyr-D-Ala-Gly-(NMe)Phe-Gly-ol;Tyr-D-Ala-Gly-N(Me)Phe-Gly-ol;Tyr-D-Ala-Gly-N-Me-Phe-Gly-ol;Ala(2)-mephe(4)-gly-ol(5) enkephalin;Tyr-D-Ala-Gly-N-Methyl-Phe-Gly-ol;D-Ala2-MePhe4-Met(0)5-enkephalin-ol;Enkephalin, Ala(2)-MePhe(4)-Gly-ol(5)-;C26H35N5O6;H-Tyr-D-Ala-Gly-N-Me-Phe-Glycinol;[D-Ala2, NMe-Phe4, Gly-ol5]-enkephalin;2YM5VT3MNR;RX783006;Dagol;L-Phenylalaninamide, L-tyrosyl-D-alanylglycyl-N-(2-hydroxyethyl)-Nalpha-methyl-;Tyr-DAla-Gly-MePhe-Gly-ol;SCHEMBL725750;GTPL1647;Tyr-D-Ala-Gly-NMePhe-Gly-ol;BDBM21015;H-Tyr-D-Ala-Gly-MePhe-Gly-ol;Tyr-D-Ala2-Gly-NMePhe-Gly-ol;DTXSID30228775;HPZJMUBDEAMBFI-WTNAPCKOSA-N;HY-P0210;Tyr-D-Ala-Gly-N(CH3)Phe-Gly-ol;H-Tyr-D-Ala-Gly-N(Me)Phe-Gly-ol;HB2409;AKOS024456435;NCGC00167303-01;(2S)-2-[[2-[[(2R)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]acetyl]-methylamino]-N-(2-hydroxyethyl)-3-phenylpropanamide;AS-83278;BD173150;BD174973;DA-72545;CS-0021316;G12226;Q5204254;[tyrosyl-3,5-3H(N)]-D-Ala2-Mephe4-glyol5-enkephalin;3: PN: WO2009046859 PAGE: 98 CLAIMED PROTEIN;158: PN: US20030176421 PAGE: 54-55 CLAIMED PROTEIN;L-TYROSYL-D-ALANYLGLYCYL-N-(2-HYDROXYETHYL)-N.ALPHA.-METHYL-L-PHENYLALANINAMIDE;L-Tyrosyl-D-alanylglycyl-N-(2-hydroxyethyl)-Nalpha-methyl-L-phenylalaninamide;(2S)-2-{2-[(2R)-2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]propanamido]-N-methylacetamido}-N-(2-hydroxyethyl)-3-phenylpropanamide;(2S)-2-amino-N-[(1R)-2-[[2-[[(1S)-1-benzyl-2-(2-hydroxyethylamino)-2-oxo-ethyl]-methyl-amino]-2-oxo-ethyl]amino]-1-methyl-2-oxo-ethyl]-3-(4-hydroxyphenyl)propanamide;(S)-2-amino-N-((R)-1-(2-(((S)-1-(2-hydroxyethylamino)-1-oxo-3-phenylpropan-2-yl)(methyl)amino)-2-oxoethylamino)-1-oxopropan-2-yl)-3-(4-hydroxyphenyl)propanamide;Benzenepropanimidic?acid, .alpha.-amino-4-hydroxy-N-[(1R,2Z)-2-hydroxy-2-[[2-[[(1S,2Z)-2-hydroxy-2-[(2-hydroxyethyl)imino]-1-(phenylmethyl)ethyl]methylamino]-2-oxoethyl]imino]-1-methylethyl]-, (.alpha.S)-; |
M.F/Formula | C26H35N5O6 |
M.W/Mr. | 513.6 |
Sequence | One Letter Code:YAGFG Three Letter Code:H-Tyr-D-Ala-Gly-N(Me)Phe-Gly-ol |
InChI | InChI=1S/C26H35N5O6/c1-17(30-25(36)21(27)14-19-8-10-20(33)11-9-19)24(35)29-16-23(34)31(2)22(26(37)28-12-13-32)15-18-6-4-3-5-7-18/h3-11,17,21-22,32-33H,12-16,27H2,1-2H3,(H,28,37)(H,29,35)(H,30,36)/t17-,21+,22+/m1/s1 |
InChI Key | HPZJMUBDEAMBFI-WTNAPCKOSA-N |
Canonical SMILES | CC(C(=O)NCC(=O)N(C)C(CC1=CC=CC=C1)C(=O)NCCO)NC(=O)C(CC2=CC=C(C=C2)O)N |
Isomeric SMILES | C[C@H](C(=O)NCC(=O)N(C)[C@@H](CC1=CC=CC=C1)C(=O)NCCO)NC(=O)[C@H](CC2=CC=C(C=C2)O)N |
3. Adipose tissue is a key organ for the beneficial effects of GLP-2 metabolic function
5. TMEM16F and dynamins control expansive plasma membrane reservoirs
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us. We will endeavor to provide highly satisfying products and services.